Group by:
Date |
Item TypeArticle
Treatment of young patients with HNF1A mutations (HNF1A-MODY).
Raile, K. and Schober, E. and Konrad, K. and Thon, A. and Grulich-Henn, J. and Meissner, T. and Woelfle, J. and Scheuing, N. and Holl, R.W.
Diabetic Medicine 32
(4): 526-530.
April 2015
Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone.
Luedtke, A. and Heck, K. and Genschel, J. and Mehnert, H. and Spuler, S. and Worman, H.J. and Schmidt, H.H.
Diabetic Medicine 22
(11): 1611-1613.
November 2005
Postprandial glucose and vascular disease.
Haller, H.
Diabetic Medicine 14
: S50-S56.
1 January 1997
Phenotyping and genotyping patients with cardiovascular risk factors.
Schuster, H.
Diabetic Medicine 14
: S57-S59.
1 January 1997
Mechanisms of hepatic chylomicron remnant clearance.
Willnow, T.E.
Diabetic Medicine 14
: S75-S80.
1 January 1997
Letter
Serum levels of L-arginine analogues and glutathione peroxidase and catalase gene variants in Type 2 diabetes mellitus patients.
Szelestei, T. and Bähring, S. and Wagner, Z. and Aydin, A. and Molnar, G.A. and Kocsis, B. and Nagy, J. and Wittmann, I.
Diabetic Medicine 22
(3): 356-357.
1 January 2005
Editorial
The postprandial state: how glucose and lipids may affect atherosclerosis and cardiovascular disease: introduction.
Haller, H.
Diabetic Medicine 14
: S5.
1 January 1997
This list was generated on Tue Apr 23 02:27:00 2024 CEST.